213 related articles for article (PubMed ID: 23870042)
41. Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.
Wong C; Duggan P
J Obstet Gynaecol; 2009 Jan; 29(1):31-4. PubMed ID: 19280492
[TBL] [Abstract][Full Text] [Related]
42. A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.
Peeker R; Samsioe G; Kowalski J; Andersson AS; Bergqvist A
Scand J Urol Nephrol; 2010 Apr; 44(3):138-46. PubMed ID: 20367449
[TBL] [Abstract][Full Text] [Related]
43. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
[TBL] [Abstract][Full Text] [Related]
44. Overactive bladder and glaucoma: a survey at outpatient clinics in Japan.
Kato K; Furuhashi K; Suzuki K; Murase T; Sato E; Gotoh M
Int J Urol; 2007 Jul; 14(7):595-7. PubMed ID: 17645600
[TBL] [Abstract][Full Text] [Related]
45. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder.
Jünemann KP; Hessdörfer E; Unamba-Oparah I; Berse M; Brünjes R; Madersbacher H; Gramatté T
Urol Int; 2006; 77(4):334-9. PubMed ID: 17135784
[TBL] [Abstract][Full Text] [Related]
46. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.
Khullar V; Cardozo L; Kelleher CJ; Hall T; Ryan J; Ebel Bitoun C; Darekar A; Arumi D; Wagg A
BJU Int; 2013 Oct; 112(6):820-9. PubMed ID: 23465055
[TBL] [Abstract][Full Text] [Related]
47. Inequities in Filled Overactive Bladder Medication Prescriptions in the US.
Luchristt D; Bretschneider CE; Kenton K; Simon M; Brown O
JAMA Netw Open; 2023 May; 6(5):e2315074. PubMed ID: 37223899
[TBL] [Abstract][Full Text] [Related]
48. Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study.
Park JS; Choi SB; Jang WS; Kim J; Ham WS
Eur Urol Focus; 2024 Feb; ():. PubMed ID: 38388215
[TBL] [Abstract][Full Text] [Related]
49. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
Lee KS; Lee HW; Choo MS; Paick JS; Lee JG; Seo JT; Lee JZ; Lee YS; Yoon H; Park CH; Na YG; Jeong YB; Lee JB; Park WH
BJU Int; 2010 Jun; 105(11):1565-70. PubMed ID: 19912183
[TBL] [Abstract][Full Text] [Related]
50. Validation of a self-administered instrument to measure adherence to anticholinergic drugs in women with overactive bladder.
Andy UU; Harvie HS; Smith AL; Propert KJ; Bogner HR; Arya LA
Neurourol Urodyn; 2015 Jun; 34(5):424-8. PubMed ID: 24719232
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder.
Armstrong EP; Malone DC; Bui CN
J Med Econ; 2012; 15 Suppl 1():35-44. PubMed ID: 22998646
[TBL] [Abstract][Full Text] [Related]
52. Healthcare and economic burden of anticholinergic use in adults with overactive bladder: a systematic literature review.
Duperrouzel C; Martin C; Mendell A; Bourque M; Carrera A; Mack A; Nesheim J
J Comp Eff Res; 2022 Dec; 11(18):1375-1394. PubMed ID: 36354285
[No Abstract] [Full Text] [Related]
53. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
54. Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes.
Johnston S; Janning SW; Haas GP; Wilson KL; Smith DM; Reckard G; Quan SP; Bukofzer S
Int J Clin Pract; 2012 Nov; 66(11):1042-51. PubMed ID: 23067028
[TBL] [Abstract][Full Text] [Related]
55. Tolterodine activates the prefrontal cortex during bladder filling in OAB patients: a real-time NIRS-urodynamics study.
Sakakibara ; Tateno F; Yano M; Takahashi O; Sugiyama M; Ogata T; Kishi M; Tsuyusaki Y; Yamamoto T; Uchiyama T; Yamanishi T; Shibata C
Neurourol Urodyn; 2014 Sep; 33(7):1110-5. PubMed ID: 24038213
[TBL] [Abstract][Full Text] [Related]
56. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
57. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
Bolge SC; McDonnell DD; Chen A; Wan GJ
Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
[TBL] [Abstract][Full Text] [Related]
58. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms.
Gopal M; Haynes K; Bellamy SL; Arya LA
Obstet Gynecol; 2008 Dec; 112(6):1311-1318. PubMed ID: 19037041
[TBL] [Abstract][Full Text] [Related]
59. Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential.
Chancellor MB; de Miguel F
Geriatrics; 2007 May; 62(5):15-24. PubMed ID: 17489643
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
